Quarterly Result28 May 2026, 05:51 pm
Board Recommends ₹1.00 Final Dividend, Approves FY26 Results
AI Summary
The Board of Directors, at its meeting on May 27, 2026, recommended a final dividend of ₹1.00 per equity share (face value ₹10.00) for the financial year ended March 31, 2026, subject to shareholder approval at the upcoming Annual General Meeting. The Board also approved the audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026, which received an unmodified opinion from M/s Rai Qimat & Associates, the statutory auditors. Additionally, M/s SPB & Co was appointed as the cost auditor and M/s Cheena & Associates as the internal auditor for the financial year 2026-27.
Key Highlights
- Board recommended a final dividend of ₹1.00 per equity share for FY26.
- Approved audited consolidated and standalone financial results for Q4 and FY26.
- Statutory auditors issued an unmodified opinion on the financial results.
- M/s SPB & Co appointed as cost auditor for FY26-27.
- M/s Cheena & Associates appointed as internal auditor for FY26-27.
Price Impact
More from MEDICAMEQ